Drug Database
PA

pasireotide (Signifor LAR / pasireotide, LAR / pasireotide LAR)

✓ Approved

Novartis AG · SSTR1 · Small Molecule

What is pasireotide?

pasireotide is a small molecule developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NamesSignifor LAR, pasireotide, LAR, pasireotide LAR
CompanyNovartis AG
Drug ClassSmall Molecule, Polypeptide
Molecular TargetSSTR1, SSTR2, SSTR3, SSTR5
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

pasireotide acts on 4 molecular targets:

SSTR1somatostatin receptor 1 (SS-1-R, SS1-R)
SSTR2somatostatin receptor 2 (SST2)
SSTR3somatostatin receptor 3 (SST3, SS3R)
SSTR5somatostatin receptor 5 (SST5, SS-5-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pasireotide is developed for 11 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersAcromegaly✓ Approved
Endocrine disordersPituitary-dependent Cushing's syndrome✓ Approved
Endocrine disordersCarcinoid syndromePhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colon cancer recurrentPhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Pituitary tumour benignPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of gastrointestinal oncology2026-05-22

Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience.

Zhao Qing Q, Li Cui-Xian CX, Chen Luo-Hai LH, Liang Yun Y et al.

Liver metastasis is a critical factor of mortality and morbidity in patients with neuroendocrine tumor, and effective management strategies remain a clinical challenge. The treatment regimen of transarterial embolization (TAE) combined with octreotide long-acting release (LAR) for the subgroup of rectal neuroendocrine tumor liver metastases (NETLMs) have not been specially investigated. This study aims to evaluate the efficacy and factors of hepatic progression-free survival (HPFS) and treatment response in patients with rectal NETLMs receiving TAE plus octreotide LAR therapy. This was a retrospective study, which enrolled 84 patients with rectal NETLMs receiving the combination therapy of TAE and octreotide LAR between January 2022 and December 2024. Patients' data were reviewed to evaluate prognostic factors of HPFS and treatment response by the univariate and multivariate Cox proportional hazards models and logistic regression models. The median HPFS was 11.1 months. Partial response (PR) in 71 patients (84.5%), stable disease (SD) in 9 patients (10.7%), and progressive disease (PD) in 4 patients (4.8%) were observed. The objective response rate (ORR) was 84.5% in the cohort. In the multivariate Cox regression model, hepatic tumor burden (HTB) ≤25% [hazard ratio (HR) =4.188, P=0.02] was an independent risk factor for HPFS. In the multivariate logistic regression model, tumor border [odds ratio (OR) =0.069, P=0.01] was a positive prognostic factor of treatment response, while 18F-fluorodeoxyglucose-positron emission tomography-computed tomography (18F-FDG PET-CT) (OR =11.919, P=0.003) and Ki-67 (OR =6.469, P=0.018) were negative prognostic factors. The therapeutic strategy of TAE combined with octreotide LAR were effective in patients with rectal NETLMs, especially in those with HTB ≤25%. Selected patients with Ki-67 ≤10%, negative 18F-FDG PET-CT and clear tumor border could derive prognostic advantage from the combination treatment.

PMID 42169939
Read full article →
PubMedFrontiers in medicine2026-05-21

Lactate dehydrogenase-to-albumin ratio predicts 30-day and 90-day mortality in glucocorticoid-treated ICU patients with pneumonia: a secondary analysis of a multicenter cohort.

Han Dandan D, Sun Shengfa S, Liu Ai A, Hao Cuiping C et al.

Glucocorticoid therapy in pneumonia patients confounds conventional inflammatory biomarkers, hindering accurate risk stratification. The lactate dehydrogenase-to-albumin ratio (LAR), a proposed steroid-resilient index reflecting cellular injury and nutritional reserve, may offer prognostic utility in this population. This secondary analysis of a multicenter cohort included 499 ICU patients with pneumonia receiving glucocorticoids. The optimal LAR cutoff for 30-day mortality was determined via the Youden index. Associations with 30- and 90-day mortality were assessed using multivariable Cox regression and propensity score matching (PSM), with doubly robust estimation serving as the primary analysis in the matched cohort. Incremental predictive value was evaluated using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). The optimal LAR cutoff was 13.39. High LAR (≥13.39) was associated with significantly higher 30-day (45.8% vs. 12.1%) and 90-day (51.4% vs. 14.3%) mortality (both p < 0.001). After full multivariable adjustment, high LAR remained an independent predictor for 30-day (HR 2.07, 95% CI 1.34-3.20) and 90-day (HR 1.93, 95% CI 1.29-2.89) mortality. In the PSM cohort, the doubly robust estimate yielded consistent findings (30-day HR 2.07, 95% CI 1.34-3.21; 90-day HR 1.93, 95% CI 1.29-2.90). Sensitivity analyses treating LAR as a continuous variable and as tertiles confirmed a dose-response relationship independent of any single threshold. LAR demonstrated good discrimination (AUC ≈ 0.74) and provided significant incremental prognostic value when added to the PSI score (NRI 0.299, p = 0.048). LAR is a simple, readily available, and steroid-resilient biomarker that independently predicts short- and mid-term mortality in pneumonia patients receiving glucocorticoids. Incorporating LAR into clinical assessment may enhance early risk stratification and guide individualized management in this challenging population.

PMID 42164156
Read full article →
PubMedJournal of comparative psychology (Washington, D.C. : 1983)2026-05-21

Personality, happiness, and health in gibbons.

Weiss Alexander A, Masilkova Michaela M, Gartner Marieke C MC, Morton F Blake FB et al.

Gibbons (family Hylobatidae) are small apes comprising lar gibbons (Hylobates spp.), crested gibbons (Nomascus spp.), siamangs (Symphalangus syndactus), and hoolocks (Hoolock spp.). These four genera are closely related to one another and to orangutans (Pongo spp.). Gibbon phylogeny and socioecology make them uniquely suited to improve our understanding of the origins of personality factors. Personality trait ratings of lar gibbons, crested gibbons, and siamangs-sufficient data on hoolocks were not available-were analyzed using exploratory factor analyses. All three genera possessed factors labeled Dominance, Extraversion, and Agreeableness. In addition, lar gibbons and siamangs possessed factors labeled Neuroticism and Conscientiousness, lar gibbons possessed a factor labeled Individualism, and crested gibbons possessed factors labeled Dyscontrol and Avoidance. Exploratory factor analysis of the combined data, which included hoolocks, revealed a Conscientiousness factor and four factors-Extraversion, Dominance, Agreeableness, and Neuroticism-that resembled four of the five orangutan personality factors. Genus- and family-level analyses revealed that better subjective well-being and health-both measured using informant ratings-were associated with higher sociability, emotional stability, and conscientiousness. Based on these results, we concluded that social group size and/or arboreality are related to factor structure, Conscientiousness evolved in hominoids 16-20 million years ago (much earlier than previous estimates), and that relationships in humans between personality and psychological and physical well-being have very early origins. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

PMID 42166318
Read full article →
PubMedJournal of intensive medicine2026-05-21

Efficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study.

Liu Ning N, Lin Fenghui F, Wen Jianli J, Yu Xiangyou X et al.

Effective sedation in intensive care unit (ICU) patients is critical for minimizing agitation, ensuring safety, and facilitating mechanical ventilation. Remimazolam tosylate, a novel benzodiazepine with rapid onset and short duration, metabolized by tissue esterases, represents a promising agent for ICU sedation. This study aimed to evaluate the efficacy and safety of remimazolam tosylate in short-term sedation for ICU patients. This was a multicenter, randomized, dose-finding, phase 2 study. From October 12, 2022 through April 19, 2023, ICU patients requiring mechanical ventilation and sedation for ≥6 h were randomized (1:1) into two groups: low adjustment rate (LAR) group received intravenous remimazolam tosylate with a maintenance rate adjustment of 0.1 mg/kg/h, and high adjustment rate (HAR) group with 0.2 mg/(kg·h). Both groups were initiated at an infusion rate of 0.2 mg/(kg·h) with the same loading dose (0.08 mg/kg) and maintenance range (0-2.0 mg/(kg·h)). The primary outcome was sedation success rate, defined as the percentage of time maintaining targeted sedation for ≥70% of the drug administration period without rescue sedation. A total of 59 patients completed the study (LAR, n=30; HAR, n=29). Within the limited sample, all patients achieved sedation success. The median percentage of time within the target sedation maintenance relative to remimazolam administration duration was 97.9% (IQR: 93.8%-99.7%) for LAR group and 98.1% (IQR: 93.6%-99.8%) for HAR group (P=0.7617). No patients required rescue sedation with propofol, and only one patient (3.3%) in LAR group required rescue analgesia with sufentanil. Most treatment-emergent adverse events (TEAEs) were mild or moderate, with hypotension (18.6%), hypertension (18.6%), and anemia (16.9%) being the most common. One serious TEAE (3.4%, disease progression) and one death were reported in HAR group, both were assessed as unrelated to remimazolam tosylate. Remimazolam tosylate demonstrated high efficacy with manageable safety profile for short-term sedation in mechanically ventilated ICU patients at both 0.1 mg/(kg·h) and 0.2 mg/(kg·h) adjustment rates.Trial registration: ClinicalTrials.gov, NCT05152303.

PMID 42164575
Read full article →
PubMedNPJ breast cancer2026-05-21

Targeting microRNA let-7b-5p-mediated aberrant androgen receptor signaling for prevention of hormone receptor-negative breast cancer.

Cando Leslie Faye LF, Sandhu Janvi J, Ju Zhenlin Z, Albarracin Constance T CT et al.

Androgen receptor, the key mediator of the AR signaling pathway, is expressed in the majority of breast cancers and has been emerging as a potential target for treatment with encouraging results in preclinical and clinical trials. But whether AR plays a role in the preneoplastic context to serve as a target for breast cancer prevention is unknown. Our results showed upregulation of AR expression in the preneoplastic and preinvasive sublines of the MCF10A breast cancer progression model. Similarly, we observed a trend towards higher expression of AR in the tumors and matched histologically normal mammary tissues of TNBC-LAR patients compared to normal noncancer controls. Mechanistically, we identified AR as a novel gene target of tumor suppressor microRNA let-7b-5p, which directly binds the AR 3' untranslated region. Mirroring AR upregulation, there was a corresponding loss of let-7b-5p expression in tumors of TNBC patients. By targeting this aberrant let-7b-5p-mediated AR signaling pathway with AR inhibitor enzalutamide, the growth and survival of preneoplastic and preinvasive lesions were significantly reduced in cell line models. Overall, our study highlights the role of let-7b-5p-mediated aberrant AR signaling in breast tumorigenesis and as a potential target for prevention in populations at risk for hormone receptor-negative breast cancer.

PMID 42162016
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-05-21

Development and validation of a nomogram based on immune-inflammation-nutrition indictors for predicting 28-day mortality in sepsis patients with severe fungal pneumonia.

Du Gongliang G, Ma Longyang L, Dang Xingbo X, Dai Wei W et al.

Severe fungal pneumonia with sepsis carries high mortality. Early and accurate prognosis is essential for improving outcomes. We developed and validated a nomogram based on immune-inflammation-nutrition indicators to predict 28-day mortality in these patients. We conducted a retrospective, exploratory cohort study analyzing 486 sepsis patients with severe fungal pneumonia, randomly splitting them into training (n=365) and validation (n=121) sets. Using LASSO regression and multivariate logistic regression, we identified independent predictors from clinical, laboratory, and immune-inflammation-nutrition data. We built a nomogram and evaluated its discrimination, calibration, and clinical utility with ROC curves, calibration plots, and decision curve analysis (DCA). Eight independent predictors entered the nomogram: respiratory failure (RF), chronic obstructive pulmonary disease (COPD), prothrombin time (PT), glucose, blood urea nitrogen (BUN), white blood cell count (WBC), albumin-to-alkaline phosphatase ratio (AAPR), and lactate-albumin ratio (LAR). The nomogram achieved AUCs of 0.884 (training) and 0.834 (validation), outperforming the SOFA score (0.740 and 0.691). Furthermore, temporal validation using an independent later cohort achieved an AUC of 0.875. Calibration curves showed good agreement between predicted and observed outcomes. DCA confirmed clinical utility across a wide range of threshold probabilities. We developed and internally validated a practical nomogram that integrates clinical variables with immune-inflammation-nutrition indicators to predict 28-day mortality in sepsis patients with severe fungal pneumonia. This tool may help clinicians with early risk stratification and individualized treatment decisions.

PMID 42164270
Read full article →

+5135 more articles available with a free account

Sign up free to view all articles →

Ask about pasireotide